Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(0.51)
# 1941
Out of 5,266 analysts
159
Total ratings
39.81%
Success rate
8.66%
Average return
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
BridgeBio Pharma | Reiterates: Overweight | 95 95 | 36.86 | 157.73% | 10 | Feb 21, 2025 | |
Krystal Biotech | Reiterates: Overweight | 215 | 187.99 | 14.37% | 5 | Feb 20, 2025 | |
Ascendis Pharma | Maintains: Outperform | 220 260 | 152.6 | 70.38% | 2 | Feb 18, 2025 | |
Septerna | Reiterates: Overweight | 50 50 | 5.85 | 754.7% | 2 | Feb 11, 2025 | |
Spero Therapeutics | Downgrades: In-Line | 5 5 | 0.83 | 502.41% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 200 200 | 35.99 | 455.71% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 25 25 | 12.23 | 104.42% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 65 65 | 10.46 | 521.41% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 16 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 30 30 | 11.28 | 165.96% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 90 90 | 37.41 | 140.58% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 15 15 | 0.76 | 1873.68% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 54 53 | 31.11 | 70.36% | 5 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 23 | 3.77 | 510.08% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 65 65 | 39.74 | 63.56% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 50 60 | 52.56 | 14.16% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 50 50 | 2.05 | 2339.02% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 75 75 | 27.87 | 169.11% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 43 5 | 1.61 | 210.56% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 40 | n/a | n/a | 1 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 20 11 | 1.41 | 680.14% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 24 15 | n/a | n/a | 3 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 2 2 | n/a | n/a | 1 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 140 130 | 120.67 | 7.73% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 760 | 701.04 | 8.41% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 15 | 14.36 | 4.46% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 50 | n/a | n/a | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 350 | n/a | n/a | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 45 | 0.03 | 149900% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 55 | 9.04 | 508.41% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 30 | 1.74 | 1624.14% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 480 | n/a | n/a | 1 | Sep 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 15 | n/a | n/a | 3 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | n/a | n/a | n/a | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 2 | Apr 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | n/a | n/a | n/a | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 222 250 | 336.44 | -25.69% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 196 0 | n/a | n/a | 2 | Sep 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 3500 4600 | 4.07 | 112922.11% | 4 | Jun 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | n/a | n/a | n/a | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 65 0 | n/a | n/a | 2 | May 8, 2018 |